• Camp4 Therapeutics closed a second tranche of a previously announced private placement, raising USD 50.1 million in gross proceeds.
• Issuance included 10,756,498 common shares at USD 1.53, 21,925,368 pre-funded warrants at USD 1.53, 39,306 shares at USD 1.65.
• Proceeds earmarked to advance CMP-002 for SYNGAP1-related disorder, including a Phase 1/2 trial cleared in Australia.
• Placement led by Leerink Partners; Piper Sandler, Cantor Fitzgerald, Wedbush acted as co-placement agents.
• Securities were sold in an unregistered transaction; investors received resale registration rights for shares underlying the pre-funded warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-052150), on August 04, 2026, and is solely responsible for the information contained therein.